GlassScriptPhysician profile
Mohammed K Faizan
NPI 1255338240
$5,925.43
in general payments reported to CMS, 2019-2025
8 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Pediatric Nephrology provider received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2022: $2,226 · 2023: $3,255 · 2024: $47.09 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,700 · Food and Beverage: $506 · Travel and Lodging: $200 · Education: $19.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,700.00 |
| Food and Beverage | $506.07 |
| Travel and Lodging | $199.62 |
| Education | $19.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $5,000.19 | 2022-2024 | Thiola |
| Alexion Pharmaceuticals, INC. | $422.45 | 2019-2023 | |
| Rhythm Pharmaceuticals, INC. | $124.60 | 2022 | |
| Baxter Healthcare | $124.59 | 2019 | |
| Novo Nordisk INC | $122.65 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $100.75 | 2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $30.20 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Faizan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.